About

Conventional chondrosarcoma is a rare cancer that forms in cartilage and is resistant to standard chemotherapy and radiation. Ozekibart is an antibody designed to bind and activate a specific "death receptor" (DR5) on the surface of cancer cells. This activation may trigger the cancer cells to self-destruct, offering a potential new treatment approach for this difficult-to-treat disease.